The HPV Vaccine Reduces Cervical Cancer Deaths to Nearly Zero in Women: The Science Explained
Author: Dr. Raywat Deonandan, PhD in Epidemiology and Biostatistics, University of Ottawa | Editors: Tashi Stampp and Romina Garcia de leon (blog coordinators)
Published: September 18th, 2026
News outlets have recently reported that young women who received the HPV vaccine have a “near 0%” chance of dying from cervical cancer. Can you explain what the researchers mean by this?
The “near 0%” wording is a shorthand for a striking population-level finding, rather than a prediction that any individual woman has literally zero risk. In the 2026 study published in The Lancet, researchers examined cervical-cancer mortality in England following the introduction of routine HPV vaccination. Among women aged 20–24 during 2020–2024 (a group in which roughly 88–90% had been vaccinated at ages 12–13), there were zero deaths from cervical cancer, whereas around 23 deaths would have been expected based on historical rates.
The researchers therefore estimated a 100% reduction in mortality in this group. (Statistically, the actual number is probably somewhere between 84% and 100%, based on what we call a “95% confidence interval”). They also estimated that England’s vaccination programme had prevented approximately 200 cervical-cancer deaths through 2024.
“Near zero” is a reasonable way of communicating that cervical-cancer mortality has become extraordinarily rare in these highly vaccinated young cohorts. But this should not be interpreted as an individual’s lifetime risk being mathematically zero.
The study also reports a 100% reduction in cervical cancer deaths in certain age groups. Is it safe to say the vaccine provides women a literal 100% guarantee of protection? Why or why not?
No. In epidemiology, an observed 100% reduction does not mean a vaccine provides a lifetime 100% guarantee to every vaccinated individual. Rather, it means that no deaths occurred in the particular population during the period studied when some deaths would otherwise have been expected.
The uncertainty around the estimate is important. As noted above, for women aged 20–24 in 2020–2024, the estimated mortality reduction was 100%, but its 95% confidence interval was 84–100%. This means that even in that observed group, there is a chance that the actual mortality reduction was 84%, not 100%. For readers unfamiliar with the arcane art of statistics, this can be understandably confusing.
Moreover, this was an observational population study rather than a randomized trial, the women are still young, and cervical cancer can occur later in life. HPV vaccines also protect against the HPV types responsible for the great majority, but not literally every possible cause of cervical cancer. So these numbers most certainly do not represent the actual lifetime risk of a randomly selected woman.
Indeed, the authors appropriately described their results as evidence that high vaccination coverage was “associated with” a substantial reduction in deaths, rather than being the cause of that reduction.
The result is nevertheless remarkable: zero cervical-cancer deaths occurred in an entire national population of women aged 20–24 over five years, compared with 23.1 expected deaths. The correct message is therefore not “the vaccine guarantees you will never die of cervical cancer,” but rather that early HPV vaccination appears capable of reducing the risk to extraordinarily low levels. And that’s a powerful, meaningful message.
Parents often wonder why the HPV vaccine is recommended in middle school, for girls as young as 11 to 13 years old. Is it safe to vaccinate at this age, and why is receiving it before exposure to HPV so important?
Yes. HPV vaccination has an extensive safety record in adolescents, and vaccination at this age is deliberate: the goal is to establish immunity before a child is ever exposed to HPV, not because anyone is making assumptions about when an individual child will become sexually active.
HPV is extremely common and is transmitted through intimate skin-to-skin contact. Once infection with a particular HPV type has occurred, vaccination cannot eliminate that existing infection. The vaccine is therefore much more useful when given beforehand.
The CDC routinely recommends vaccination at ages 11–12 and permits it beginning at age 9, and notes that more than 15 years of monitoring support its safety, effectiveness, and durability. Common adverse effects are generally mild, such as injection-site pain, headache, or fever. Serious allergic reactions are rare.
Importantly, the new English mortality data provide unusually powerful real-world support for the timing of vaccination: the most dramatic reduction in cervical-cancer deaths occurred in the cohorts vaccinated at 12–13 years, when most recipients had not yet been exposed to HPV.
Vaccinating early is therefore best understood as preventive medicine in its purest form: establish protection years before the infection that can eventually cause cancer is likely to occur.
Can you explain what herd immunity is, and why maintaining high HPV vaccination rates is still important, even when many people in a community are vaccinated?
Herd immunity occurs when enough people in a population are immune to an infection that transmission becomes less likely. Importantly, this indirectly protects people who are not immune. The threshold for what determines “enough people” varies depending on many things, including how contagious a disease is, and the effectiveness of both vaccination and prior infection in conferring immunity.
With HPV, high vaccination coverage reduces the number of people carrying and transmitting vaccine-targeted HPV types, so even unvaccinated people can benefit. Studies have found declines in vaccine-targeted HPV infections among unvaccinated populations following vaccination programs that are consistent with herd immunity expectations.
But herd immunity is not an all-or-nothing threshold, and HPV presents particular challenges because it is extremely common, includes many different viral types, and spreads through intimate skin-to-skin contact. If vaccination coverage falls, more susceptible people enter the population and transmission can increase again, weakening that indirect protection.
Maintaining high coverage also matters for equity. People do not mix randomly, so national or provincial vaccination rates can conceal schools, communities, or social networks with much lower coverage. The goal, therefore, is not simply to reach some magic percentage and stop vaccinating. Rather, sustained high uptake provides strong direct protection to each new generation while also reducing circulation of cancer-causing HPV types throughout the population.
If the HPV vaccine is so effective, why is cervical cancer screening still important for women who have been vaccinated?
Cervical cancer screening remains important because HPV vaccination dramatically reduces risk but does not eliminate it. Current vaccines protect against the HPV types responsible for most cervical cancers. But they do not protect against every cancer-causing HPV type, and some women may have been exposed to HPV before vaccination or may not have received the full benefit of vaccination.
Screening (using HPV testing, Pap testing, or both, depending on local guidelines) provides a second layer of protection by detecting high-risk HPV infections or precancerous cervical changes before they develop into invasive cancer.
Vaccination and screening should therefore be viewed as complementary rather than competing strategies. Vaccination prevents most of the infections that cause cervical cancer, while screening identifies the smaller number of potentially dangerous infections that still occur. This combination is central to the World Health Organization’s strategy for eliminating cervical cancer as a public-health problem, which pairs high HPV vaccination coverage with high screening and treatment coverage.
